Whole body irradiation with intensity-modulated helical tomotherapy prior to haematopoietic stem cell transplantation: analysis of organs at risk by dose and its effect on blood kinetics.
Acute lymphocytic leukaemia
Acute myeloid leukaemia
Blood kinetics
Bone marrow transplantation
Dose sparing
Helical tomotherapy
Neutral killer cell lymphoma
Total body irradiation
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
25
01
2023
accepted:
15
02
2023
medline:
31
7
2023
pubmed:
2
3
2023
entrez:
1
3
2023
Statut:
ppublish
Résumé
Intensity-modulated helical tomotherapy (HT) is a promising technique in preparation for bone marrow transplantation. Nevertheless, radiation-sensitive organs can be substantially compromised due to suboptimal delivery techniques of total body irradiation (TBI). To reduce the potential burden of radiation toxicity to organs at risk (OAR), high-quality coverage and homogeneity are essential. We investigated dosimetric data from kidney, lung and thorax, liver, and spleen in relation to peripheral blood kinetics. To further advance intensity-modulated total body irradiation (TBI), the potential for dose reduction to lung and kidney was considered in the analysis. 46 patients undergoing TBI were included in this analysis, partially divided into dose groups (2, 4, 8, and 12 Gy). HT was performed using a rotating gantry to ensuring optimal reduction of radiation to the lungs and kidneys and to provide optimal coverage of other OAR. Common dosimetric parameters, such as D05, D95, and D50, were calculated and analysed. Leukocytes, neutrophils, platelets, creatinine, GFR, haemoglobin, overall survival, and graft-versus-host disease were related to the dosimetric evaluation using statistical tests. The mean D95 of the lung is 48.23%, less than half the prescribed and unreduced dose. The D95 of the chest is almost twice as high at 84.95%. Overall liver coverage values ranged from 96.79% for D95 to 107% for D05. The average dose sparing of all patients analysed resulted in an average D95 of 68.64% in the right kidney and 69.31% in the left kidney. Average D95 in the spleen was 94.28% and D05 was 107.05%. Homogeneity indexes ranged from 1.12 for liver to 2.28 for lung. The additional significance analyses conducted on these blood kinetics showed a significant difference between the 2 Gray group and the other three groups for leukocyte counts. Further statistical comparisons of the dose groups showed no significant differences. However, there were significant changes in the dose of OAR prescribed with dose sparing (e.g., lung vs. rib and kidney). Using intensity-modulated helical tomotherapy to deliver TBI is a feasible method in preparation for haematopoietic stem cell transplantation. Significant dose sparing in radiosensitive organs such as the lungs and kidneys is achievable with good overall quality of coverage. Peripheral blood kinetics support the positive impact of HT and its advantages strongly encourage its implementation within clinical routine.
Sections du résumé
BACKGROUND
BACKGROUND
Intensity-modulated helical tomotherapy (HT) is a promising technique in preparation for bone marrow transplantation. Nevertheless, radiation-sensitive organs can be substantially compromised due to suboptimal delivery techniques of total body irradiation (TBI). To reduce the potential burden of radiation toxicity to organs at risk (OAR), high-quality coverage and homogeneity are essential. We investigated dosimetric data from kidney, lung and thorax, liver, and spleen in relation to peripheral blood kinetics. To further advance intensity-modulated total body irradiation (TBI), the potential for dose reduction to lung and kidney was considered in the analysis.
PATIENTS AND METHODS
METHODS
46 patients undergoing TBI were included in this analysis, partially divided into dose groups (2, 4, 8, and 12 Gy). HT was performed using a rotating gantry to ensuring optimal reduction of radiation to the lungs and kidneys and to provide optimal coverage of other OAR. Common dosimetric parameters, such as D05, D95, and D50, were calculated and analysed. Leukocytes, neutrophils, platelets, creatinine, GFR, haemoglobin, overall survival, and graft-versus-host disease were related to the dosimetric evaluation using statistical tests.
RESULTS
RESULTS
The mean D95 of the lung is 48.23%, less than half the prescribed and unreduced dose. The D95 of the chest is almost twice as high at 84.95%. Overall liver coverage values ranged from 96.79% for D95 to 107% for D05. The average dose sparing of all patients analysed resulted in an average D95 of 68.64% in the right kidney and 69.31% in the left kidney. Average D95 in the spleen was 94.28% and D05 was 107.05%. Homogeneity indexes ranged from 1.12 for liver to 2.28 for lung. The additional significance analyses conducted on these blood kinetics showed a significant difference between the 2 Gray group and the other three groups for leukocyte counts. Further statistical comparisons of the dose groups showed no significant differences. However, there were significant changes in the dose of OAR prescribed with dose sparing (e.g., lung vs. rib and kidney).
CONCLUSION
CONCLUSIONS
Using intensity-modulated helical tomotherapy to deliver TBI is a feasible method in preparation for haematopoietic stem cell transplantation. Significant dose sparing in radiosensitive organs such as the lungs and kidneys is achievable with good overall quality of coverage. Peripheral blood kinetics support the positive impact of HT and its advantages strongly encourage its implementation within clinical routine.
Identifiants
pubmed: 36856852
doi: 10.1007/s00432-023-04657-7
pii: 10.1007/s00432-023-04657-7
pmc: PMC10374741
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7007-7015Informations de copyright
© 2023. The Author(s).
Références
Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):521-529
pubmed: 29893272
Cancers (Basel). 2021 Jun 12;13(12):
pubmed: 34204603
J Med Phys. 2012 Oct;37(4):207-13
pubmed: 23293452
Jpn J Radiol. 2018 Apr;36(4):241-256
pubmed: 29508261
J Egypt Natl Canc Inst. 2016 Mar;28(1):7-11
pubmed: 26300327
Technol Cancer Res Treat. 2009 Feb;8(1):29-38
pubmed: 19166240
Anticancer Res. 2016 Sep;36(9):4859-64
pubmed: 27630341
Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):1025-1033
pubmed: 31421151
Eur J Cancer. 2021 Jan;143:1-10
pubmed: 33271483
J Cancer Res Clin Oncol. 2023 Aug;149(9):5965-5973
pubmed: 36607428
Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):323-332
pubmed: 28068240
Cancer Res Treat. 2017 Jan;49(1):92-103
pubmed: 27188204
Bone Marrow Transplant. 2008 Mar;41(5):439-46
pubmed: 18334992
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1228-32
pubmed: 16682132
Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1259-67
pubmed: 17336225
Eur J Med Res. 2022 Dec 10;27(1):287
pubmed: 36496388
Bone Marrow Transplant. 2011 Jul;46(7):929-35
pubmed: 20935684
Semin Nephrol. 2010 Nov;30(6):615-26
pubmed: 21146126
Adv Radiat Oncol. 2021 Jul 29;6(6):100761
pubmed: 34934857
Phys Med. 2019 Apr;60:162-167
pubmed: 31000078
Adv Chronic Kidney Dis. 2014 Jan;21(1):96-105
pubmed: 24359992
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6
pubmed: 7713792
Bone Marrow Transplant. 2012 Nov;47(11):1484-5
pubmed: 22465975
Adv Radiat Oncol. 2018 Feb 21;3(3):297-304
pubmed: 30202799
J Clin Oncol. 2009 Sep 20;27(27):4570-7
pubmed: 19652066
Z Med Phys. 2020 Feb;30(1):17-23
pubmed: 31239184
Eur J Med Res. 2022 Nov 24;27(1):265
pubmed: 36434707
Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):273-9
pubmed: 18786784
Curr Oncol. 2021 Feb 14;28(1):903-917
pubmed: 33617507
Strahlenther Onkol. 2014 May;190(5):453-8
pubmed: 24595415
Cancers (Basel). 2020 Dec 23;13(1):
pubmed: 33374564
Eur J Haematol. 2021 Oct;107(4):393-407
pubmed: 34107104
Br J Cancer. 2004 Jun 1;90(11):2080-4
pubmed: 15150598
Blood. 1999 May 15;93(10):3259-66
pubmed: 10233877
Cancer Med. 2023 Mar;12(6):7170-7174
pubmed: 36404470
Radiat Oncol. 2013 Apr 15;8:92
pubmed: 23587349
Med Phys. 2005 Oct;32(10):3214-24
pubmed: 16279075
Lancet Haematol. 2019 Apr;6(4):e183-e193
pubmed: 30878319
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S70-6
pubmed: 20171521
Bone Marrow Transplant. 2016 Mar;51(3):351-7
pubmed: 26618548